
Please try another search
Second Sight Medical Products (NASDAQ:EYES) has found a market niche for itself in the healthcare space developing implantable visual prosthetics to treat sight-impaired people. With the U.S. FDA approval for its Argus 2s Retinal Prosthesis System in hand, can the stock keep soaring in the coming months? Let’s find out.Second Sight Medical Products, Inc. (EYES) has been in operation for more than two decades. It develops, manufactures and markets implantable visual prosthetics that are designed to deliver artificial vision to sight-impaired individuals. EYES’ shares soared to hit their 52-week high of $20 on March 9, following the FDA’s approval of its Argus 2s Retinal Prosthesis System. The stock has rallied 20.9% over the past three months to close yesterday’s trading session at $7.
According to Business Wire, the Vision Care market is expected to grow at a 4.31% CAGR between 2019 and 2027.
However, EYES’ next generation Orion Visual Cortical Prosthesis System is still under development. Also, the company is alleged to have violated its MOU with Pixium Vision SA. So, with a narrow portfolio of products and solutions, EYES’ prospects look bleak.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.